Methylphenidate and Metabolite, Urine, Quantitative
2003115
Ordering Recommendation
Useful for general testing in contexts of compliance and/or abuse. Preferred test to follow-up presumptive results.
Mnemonic
METHPHENUR
Methodology
Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Performed
Mon, Thu
Reported
1-7 days
New York DOH Approval Status
This test is New York DOH approved.
Submit With Order
Specimen Required
- Patient Preparation
- Collect
- Random urine.
- Specimen Preparation
- Transfer 2 mL urine with no additives or preservatives to an ARUP Standard Transport Tube. (Min: 1 mL)
- Storage/Transport Temperature
- Refrigerated.
- Unacceptable Conditions
- Room temperature specimens.
- Remarks
- Stability
- Ambient: Unacceptable; Refrigerated: 3 weeks; Frozen: 3 months
Reference Interval
Effective August 17, 2015
| Drugs Covered | Methylphenidate |
| Methylphenidate | 10 ng/mL |
| Ritalinic acid | 100 ng/mL |
Interpretive Data
Methodology: Quantitative Liquid Chromatography-Tandem Mass Spectrometry
Positive Cutoff: Methylphenidate: 10 ng/mL
Ritalinic acid: 100 ng/mL
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
Positive Cutoff: Methylphenidate: 10 ng/mL
Ritalinic acid: 100 ng/mL
The absence of expected drug(s) and/or drug metabolite(s) may indicate non-compliance, inappropriate timing of specimen collection relative to drug administration, poor drug absorption, diluted/adulterated urine, or limitations of testing. The concentration value must be greater than or equal to the cutoff to be reported as positive. Interpretive questions should be directed to the laboratory.
Compliance Statement B: This test was developed and its performance characteristics determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.
Note
CPT Code(s)
80360 (Alt code: G0480)
Components
| Component Test Code* | Component Chart Name | LOINC |
|---|---|---|
| 2003116 | Methylphenidate, Urn, Quant | 3809-1 |
| 2003117 | Ritalinic acid, Urn, Quant | 33507-5 |
Aliases
- Attenade
- Concerta
- Daytrana
- Dexmethylphenidate
- Focalin (Methylphenidate and Metabolite - Confirmation/Quantitation - Urine)
- Metadate
- Methylin
- Methylphenidate
- Ritalin
- Ritalinic Acid
- Urine ritalin concentration